Dermatology

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Webinars
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at [email protected] Contact no. 011-43720751

Home

Ruchika Sharma

Articles By : Ruchika Sharma

Emcure Pharma Gets CDSCO Panel Nod to Conduct Phase IV Trial on Drospirenone Tablets

USFDA issues EIR for Emcure Pharma Pune API facility

Written By Ruchika Sharma19 April 2025 12:15 PM IST

Pune: In a recent BSE filing, Emcure Pharma has informed that the Company has received the Establishment Inspection Report (EIR) from the...

JB Chemicals gets USFDA nod for hypertension drug Bisoprolol

Written By Ruchika Sharma19 April 2025 11:21 AM IST

Mumbai: J.B. Chemicals & Pharmaceuticals Limited has announced that the company has received approval from the United States Food and...

Boehringer Ingelheim appoints Shashank Deshpande as Chairman of Board of Managing Directors

Written By Ruchika Sharma18 April 2025 4:31 PM IST

Ingelheim: Boehringer Ingelheim has announced that Shashank Deshpande, member of the Board of Managing Directors, has been appointed Chairman of the...

USFDA Approves Corcept Therapeutics Ovarian Cancer Drug Lifyorli

USFDA approves Alembic Pharma anticonvulsant drug Carbamazepine

Written By Ruchika Sharma18 April 2025 12:47 PM IST

Vadodara: Alembic Pharmaceuticals Limited announced that the US Food & Drug Administration (USFDA) has approved its Abbreviated New Drug...

USFDA updates Camzyos label to reduce echocardiography monitoring requirements, contraindications: Bristol Myers Squibb

Written By Ruchika Sharma18 April 2025 11:00 AM IST

Princeton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has updated the U.S. Prescribing Information for...

Lupin Gets USFDA Approval for Xigduo XR Generic Dapagliflozin-Metformin Tablets

USFDA issues EIR for Lupin Nagpur Injectable facility

Written By Ruchika Sharma17 April 2025 3:00 PM IST

Mumbai: Global pharma major Lupin Limited has announced that it has received the Establishment Inspection Report (EIR) from the United States Food...

Abbott India appoints Anushree Kunhambu as Associate Director - New Product Introduction and Therapy Area Strategy

Abbott India names Anushree Kunhambu as Associate Director - New Product Introduction and Therapy Area Strategy

Written By Ruchika Sharma16 April 2025 3:35 PM IST

Mumbai: Abbott India has announced the appointment of Anushree Kunhambu as Associate Director - New Product Introduction and Therapy Area...

USFDA Closes Inspection at Zydus Ankleshwar Unit-2 With Three Observations

Laurus Labs gets USFDA EIR for Atchutapuram facility

Written By Ruchika Sharma16 April 2025 11:30 AM IST

Andhra Pradesh: Laurus Labs has announced that the company has received the Establishment Inspection Report (EIR) from the United States Food...

Shilpa Biologicals, Stein Cares Ink Exclusive Biosimilar Licensing Pact for Latin America

Boehringer Ingelheim, Cue Biopharma partner to develop next generation treatment for autoimmune, inflammatory diseases

Written By Ruchika Sharma16 April 2025 10:30 AM IST

Boston: Boehringer Ingelheim and Cue Biopharma, Inc. have announced a strategic research collaboration and license agreement to develop and...

Bristol Myers Squibb Wins USFDA Approval for Opdivo Combo in Hodgkin Lymphoma

Bristol Myers Squibb heart disease drug fails to meet main goals in late-stage study

Written By Ruchika Sharma16 April 2025 9:30 AM IST

Princeton: Bristol Myers Squibb has announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment of adult...

Biocon Biologics Secures BB+ Rating Upgrade from S&P on Improved Financial Metrics

Biocon Biologics secures market entry date for ophthalmology drug Yesafili in US

Written By Ruchika Sharma15 April 2025 4:18 PM IST

Additionally, Biocon Biologics secured a settlement agreement in Canada with Bayer and Regeneron Pharma for launch of YESAFILI no later than July 1,...

AstraZeneca Pharma India surrenders marketing authorisation for specific indication of Olaparib

Written By Ruchika Sharma15 April 2025 3:46 PM IST

Bangalore: AstraZeneca Pharma India Limited has surrendered its marketing authorisation for Olaparib film-coated tablets 100mg and 150mg...

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok